Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC) Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Kim, E. S.; Velcheti, V.; Mekhail, T.; Leal, T. A.; Dowell, J. E.; Tsai, M. L.; Dakhil, C. S. R.; Stella, P.; Shen, V.; Hu, S.; Paul, S. M.; Shames, D. S.; Schleifman, E.; Fabrizio, D. A.; Yun, C.; Phan, S.; Socinski, M. A.

authors

Publication Date

  • October 1, 2018

webpage

published in

category

start page

  • 744

end page

  • 744

volume

  • 29